U.S. Markets closed
  • S&P 500

    4,326.51
    -23.42 (-0.54%)
     
  • Dow 30

    34,160.78
    -7.31 (-0.02%)
     
  • Nasdaq

    13,352.78
    -189.34 (-1.40%)
     
  • Russell 2000

    1,931.29
    -45.18 (-2.29%)
     
  • Crude Oil

    87.20
    +0.59 (+0.68%)
     
  • Gold

    1,795.00
    +1.90 (+0.11%)
     
  • Silver

    22.71
    +0.03 (+0.15%)
     
  • EUR/USD

    1.1147
    0.0000 (-0.0000%)
     
  • 10-Yr Bond

    1.8070
    -0.0410 (-2.22%)
     
  • Vix

    30.49
    -1.47 (-4.60%)
     
  • GBP/USD

    1.3388
    +0.0006 (+0.0482%)
     
  • USD/JPY

    115.4450
    +0.1430 (+0.1240%)
     
  • BTC-USD

    37,157.66
    +111.50 (+0.30%)
     
  • CMC Crypto 200

    840.28
    +20.77 (+2.53%)
     
  • FTSE 100

    7,554.31
    +84.53 (+1.13%)
     
  • Nikkei 225

    26,317.24
    +146.94 (+0.56%)
     

Adaptimmune Stock Soars on Roche Pact to Commercialize Cancer Therapy

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • ADAP
  • ROG.SW

By Dhirendra Tripathi

Investing.com – Adaptimmune stock (NASDAQ:ADAP) was locked at 20% gains after the stock climbed on announcing a tie-up with Roche (OTC:RHHBY) for commercializing cancer therapies.

The two companies will collaborate on research and development of ‘off-the-shelf’ cell therapies for up to five shared cancer targets and the development of a novel allogeneic personalized cell therapy platform.

The tie-up seeks to make cell therapies both curative and mainstream by enabling any patient to receive a T-cell product for their cancer.

Adaptimmune will use its platform to develop clinical candidates to produce T-cells. Roche's Genentech unit will be responsible for subsequent clinical development and commercialization.

Under the terms of the agreement, Adaptimmune will receive $150 million upfront and $150 million additionally over five years. Adaptimmune may also be eligible to receive research, development, regulatory and commercial milestone payments potentially exceeding $3 billion in aggregate value.

Related Articles

Adaptimmune Stock Soars on Roche Pact to Commercialize Cancer Therapy

Federer-backed shoemaker On aims for over $12 billion valuation in U.S. IPO

World shares hold steady near record highs on dovish Fed bets